The physiological action of picolinic acid in the human brain

International Journal of Tryptophan Research

Volumn 2, Issue 1, 2009, Pages 71-79

  Grant, R S ^a,b   Coggan, S E ^a   Smythe, G A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79956371387     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/ijtr.s2469     Document Type: Review

References (73)

1. Dazzi, C, Candiano G, Massazza S, Ponzetto A, Varesio L. New highperformance liquid chromatographic method for the detection of picolinic acid in biological fluids. J Chromatogr. 2001;751:61-8.
2. Smythe GA, Braga O, Brew BJ, et al. Concurrent Quantification of Quinolinic, Picolinic, and Nicotinic Acids Using Electron-Capture Negative-Ion Gas Chromatography Mass Spectrometry. Anal Biochem. 2002;301:21-6.
3. Rebello T, Lonnerdal B, Hurley LS. Picolinic acid in milk, pancreatic juice, and intestine: inadequate for role in zinc absorption. Am J Clin Nutr. 1982;35:1-5.
4. Peters JC. Tryptophan nutrition and metabolism: an overview. Adv Exp Med Biol. 1991;294:345-58.
5. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for Increased de Novo Synthesis of NAD in Immune-Activated RAW264.7 Macrophages: A Self-Protective Mechanism? Arch Biochem Biophys. 1999;372:1-7.
6. Grant R, Kapoor V. Inhibition of indoleamine 2,3-dioxygenase activity in IFN-[gamma] stimulated astroglioma cells decreases intracellular NAD levels. Biochem Pharmacol. 2000;66:1033-6.
7. Mehler AH. Formation of picolinic and quinolinic acids following enzymatic oxidation of 3-hydroxyanthranilic acid. J Biol Chem. 1956;218(1):241-54.
8. Smythe GA, Poljak A, Bustamante S, et al. ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. Adv Exp Med Biol. 2003;527:705-12.
9. Heyes M, Saito K, Crowley J, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. Brain. 1992;115:1249-73.
10. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49:15-23.
11. Rejdak K, Bartosik-Psujek H, Dobosz B, et al. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett. 2002;4; 331(1):63-5.
12. Hartai Z, Juhasz A, Rimanoczy A. et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int. 2007;50:308-13.
13. Medana IM, Day NPJ, Salahifar-Sabet H. et al. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J Infect Dis. 2003;188: 844-9.
14. Guillemin G J, Meininger V, Brew BJ. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis. 2005;2:166-76.
15. Heyes MP, Brew BJ, Martin A. et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol. 1991;29:202-9.
16. Robinson RA, Green RW. Some Physical Properties of Aqueous Picolinic Acid Solutions J Phys Chem. 1961;65(6):1084.
17. Suzuki K, Yasuda M, Yamasaki K. Stability constants of picolinic and quinaldic acid chelates of bivalent metals. J Phys Chem. 1957;61: 229-31.
18. Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in diabetes mellitus-a review. Diabetes. Technol. Ther. 2006;8:677-87.
19. Sainio E, Sainio P. Comparison of effects of Nicotinic acid or Tryptophan on tryptophan 2,3-dioxygenase in acute and chronic studies. Toxicol Appl Pharmacol. 1990;102:251-8.
20. Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Archiv Biochem Biophys. 1980;203: 343-51.
21. Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem J. 1985;230:635-8.
22. Botting NP. Chemistry and Neurochemistry of the Kynurenine pathway of Tryptophan metabolism. Chemical Society Reviews 1995;401-12.
23. Ishimura Y, Nozaki M, Hayaishi O. The oxygenated form of L-tryptophan 2,3-dioxygenase as reaction intermediate. J Biol Chem. 1970;245:3593-602.
24. Saito K, Markey SP, Heyes MP. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience. 1992;51:25-39.
25. Ikeda M, Tsuji S, Nakamura S, Ichiyama A, Nishuzuka Y, Hayaishi O. Studies on the biosynthesis of nicotinamide adenine dinucleotide. ii. A role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. J Biol Chem. 1965;240:1395-401.
26. Bender DA, McCreaner GM. Kynurenine hydroxylase: a potential rate limiting enzyme in tryptophan metabolism. Biochemical Society Transactions. 1985;13:441-3.
27. Salter M, Knowles RG, Pogson CI. Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. Biochem J. 1986;234:635-47.
28. Pucci L, Perozzi S, Cimadamore F, Orsomando G, Raffaelli N. Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. FEBS J. 2007;274:827-40.
29. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303:1-10.
30. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78: 842-53.
31. Heyes MP, Achim CL, Wiley CA, Major EO, Sato K, Markey SP. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 1996;320:595-7.
32. Hwu P, Du MX, Lapointe R, Do M, Taylor M W, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000;164:3596-9.
33. Owe-Young R. Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem. 2008;105:1346-57.
34. Jhamandas KH, Boegman RJ, Beninger RJ, Miranda AF, Lipic KA. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox Res. 2000;2:139-155.
35. Beninger RJ, Colton AM, Ingles JL, Jhamandas K, Boegman RJ. Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neurosci Res. 1994;61:603-12.
36. Cockhill J, Jhamandas K, Boegman RJ, Beninger RJ. Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage. Brain Res. 1992;599: 57-63.
37. Melillo G, Cox GW, Biragynn A, Sheffler LA, Varesiot L. Regulation of Nitric-oxide Synthase mRNA Expression by Interferon-y and Picolinic Acid. J Biol Chem.1994;269:8128-33.
38. Varesio L, Clayton M, Blasi E, Ruffman R, Radzioch D. Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of IFN-y-primed macrophages. J Immunol. 1990;145: 4265-71.
39. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1a and -1b in Macrophages. J Immunol. 2000;164:3283-91.
40. Fernandez-Pol JA, Johnson GS. Selective toxicity induced by picolinic acid in simian virus 40-transformed cells in tissue culture. Cancer Res. 1977;37:4276-9.
41. Fernandez-Pol JA, Klos DJ, Hamilton PD. Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. Anticancer Res. 2001;21:3773-6.
42. Blasi E, Radzioch D, Varesio L. Inhibition of Retroviral mRNA expression in the murine macrophage cell line GG2EE by biological response modifiers. J Immunol. 1988;141:2153-7.
43. Cai S, Sato K, Shimizu T, Yamabe S, Hiraki M, Sano C, Tomioka H. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones. J Antimicrob Chemother. 2006;57:85-93.
44. Shimizu T, Tomioka H. Activity of Picolinic Acid in Combination with the Antiprotozoal Drug Quinacrine against Mycobacterium avium Complex. Antimicrob Agents Chemother. 2006;50:3186-8.
45. Ruffman R, Schlick R, Chirigos MA, Budzynsky W, Varesio, L. Antiproliferative activity of picolinic acid due to macrophage activation. Drugs Exp Clin Res. 1987;13:604-14.
46. Coggan SE, Smythe GA, Bilgin A, Grant RS. Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid. J Neurochem. 2009;08:1220-5.
47. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci. 2005b;239:31-5.
48. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand. 2005a; 112:93-6.
49. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 2004;17:455-61.
50. Brown R, Ozaki S, Datta S, Borden E, Sondel P, Malone D. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol. 1991;294:425-35.
51. Heyes MP, Ellis RJ, Ryan L, et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain. 2001;124:1033-1042.
52. Heyes MP, Saito K, Major EO, Milstien SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain Res. 1993;116(Pt 6):1425-50.
53. Clark CJ, Mackay GM, Smythe GA, Bustamante S, Stone TW, Phillips RS. Prolonged Survival of a Murine Model of Cerebral Malaria by Kynurenine Pathway Inhibition. Infect Immun. 2005;73: 5249-51.
54. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid-IgG and beta2-microglobulin changes. Neurosignals. 2005;14(3):126-35.
55. Comai S, Costa CVL, Ragazzi E, Bertazzo A, Allegri G. The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in rats. Clin Chim Acta. 2005;360:67-80.
56. Kennedy JS, Gwirtsman HE, Schmidt DE, et al. Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. Life Sci. 2002;71:1703-15.
57. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-3.
58. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J. 2005;19:1347-9.
59. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-74.
60. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007;67: 792-801.
61. Tanabe A, Egashira Y, Fukuoka S, et al. Expression of rat hepatic 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase is affected by a high protein diet and by streptozotocin-induced diabetes. J Nutr. 2002;132:1153-9.
62. Egashira Y, Murotani G, Tanabe A, et al. Differential effects of dietary fatty acids on rat liver alpha-amino-beta-carboxymuconate-epsilonsemialdehyde decarboxylase activity and gene expression. Biochim Biophys Acta. 2004;1686:118-24.
63. Egashira Y, Ogawara R, Ohta T, Sanada H. Suppression of rat hepatic a-amino-b-carboxymuconate- e-semialdehyde decarboxylase (ACMSD) activity by linoleic acid in relation to its induction by glucocorticoids and dietary protein. Biosci Biotech Biochem. 1994;58.
64. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisomeproliferator regulates key enzymes of the tryptophan-NAD+ pathway. Toxicol Appl Pharmacol.1999;158:71-80.
65. Fukuwatari T, Ohsaki S, Fukuoka S, Sasaki R, Shibata K. Phthalate Esters Enhance Quinolinate Production by Inhibiting Amino-β-Carboxymuconate-Semialdehyde Decarboxylase (ACMSD), a Key Enzyme of the Tryptophan Pathway. Toxicol Sci. 2004;81: 302-308.
66. Szepesi B, Freedland RA. Time-course of changes in rat liver enzyme activities after initiation of a high protein regimen. J Nutr. 1968;94(4): 463-468.
67. Yasumatsu N, Yoshikawa Y, Adachi Y, Sakurai H. Antidiabetic copper(II)-picolinate: impact of the first transition metal in the metallopicolinate complexes. Bioorg Med Chem. 2007;15(14):4917-22.
68. Reading SA. Chromium picolinate. J Fla Med Assoc. 1996; 83:29-31.
69. Aggett, P J, Fenwick PK, Kirk H. An In Vitro Study of the Effect of Picolinic Acid on Metal Translocation across Lipid Bilayers. J Nutr. 1989;119:1432-7.
70. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007-2017.
71. Stone TW. Neuropharmacology of quinolinic acids and kynurenic acids. Pharmacol Rev. 1993;45:309-79.
72. Baran H, Cairns N, Lubec B, Lubec G. Increased kynurenic acid levels and decreased brain kynuenine aminotransferase in parients with downs syndrome. Life Sci. 1996;58:1891-9.
73. Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lteral sclerosis. Acta Neurol Scand. 2003;107:412-8.